Based on the findings of this study, CompC reduced tumor cell growth by inhibiting the expression and phosphorylation of cell cycle regulatory proteins, such as pRb, Cdks and cyclins, and by increasing the levels of Cdk inhibitors, which resulted in G2/M-phase cell cycle arrest in B16-F1 cells. The gene discussed is PCNA; the disease is neoplasm.